EP1390390A4 - Human secreted proteins - Google Patents

Human secreted proteins

Info

Publication number: EP1390390A4
Authority: EP; European Patent Office
Prior art keywords: secreted proteins; human secreted; human; proteins; secreted
Prior art date: 2001-03-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP02799146A

Other languages

German (de)

French (fr)

Other versions

EP1390390A2 (en

Inventor

Craig A Rosen

Steven M Ruben

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Human Genome Sciences Inc

Original Assignee

Human Genome Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-21

Filing date

2002-03-19

Publication date

2009-07-08

2002-03-19 Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc

2004-02-25 Publication of EP1390390A2 publication Critical patent/EP1390390A2/en

2009-07-08 Publication of EP1390390A4 publication Critical patent/EP1390390A4/en

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Obesity (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Zoology (AREA)
Emergency Medicine (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

EP02799146A 2001-03-21 2002-03-19 Human secreted proteins Withdrawn EP1390390A4 (en)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US27734001P	2001-03-21	2001-03-21
US277340P		2001-03-21
US30617101P	2001-07-19	2001-07-19
US306171P		2001-07-19
US33128701P	2001-11-13	2001-11-13
US331287P		2001-11-13
PCT/US2002/008277 WO2003038063A2 (en)	2001-03-21	2002-03-19	Human secreted proteins

Publications (2)

Publication Number	Publication Date
EP1390390A2 EP1390390A2 (en)	2004-02-25
EP1390390A4 true EP1390390A4 (en)	2009-07-08

Family

ID=27402891

Family Applications (7)

Application Number	Title	Priority Date	Filing Date
EP02782476A Withdrawn EP1414845A4 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02723499A Withdrawn EP1379264A4 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02759068A Withdrawn EP1404702A4 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02749512A Withdrawn EP1381622A2 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02780789A Withdrawn EP1423134A2 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02799146A Withdrawn EP1390390A4 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02760994A Withdrawn EP1379132A4 (en)	2001-03-21	2002-03-19	Human secreted proteins

Family Applications Before (5)

Application Number	Title	Priority Date	Filing Date
EP02782476A Withdrawn EP1414845A4 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02723499A Withdrawn EP1379264A4 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02759068A Withdrawn EP1404702A4 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02749512A Withdrawn EP1381622A2 (en)	2001-03-21	2002-03-19	Human secreted proteins
EP02780789A Withdrawn EP1423134A2 (en)	2001-03-21	2002-03-19	Human secreted proteins

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP02760994A Withdrawn EP1379132A4 (en)	2001-03-21	2002-03-19	Human secreted proteins

Country Status (4)

Country	Link
EP (7)	EP1414845A4 (en)
AU (6)	AU2002324424A1 (en)
CA (7)	CA2441702A1 (en)
WO (7)	WO2002102993A2 (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999002546A1 (en)	1997-07-08	1999-01-21	Human Genome Sciences, Inc.	123 human secreted proteins
US7196164B2 (en)	1997-07-08	2007-03-27	Human Genome Sciences, Inc.	Secreted protein HHTLF25
US20060052321A1 (en)	2002-04-05	2006-03-09	Raitano Arthur B	Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US6833438B1 (en)	1999-06-01	2004-12-21	Agensys, Inc.	Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040141975A1 (en)	1998-06-01	2004-07-22	Raitano Arthur B.	Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20030149531A1 (en)	2000-12-06	2003-08-07	Hubert Rene S.	Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6329503B1 (en)	1998-06-01	2001-12-11	Agensys, Inc.	Serpentine transmembrane antigens expressed in human cancers and uses thereof
AU2507700A (en)	1999-01-15	2000-08-01	Biogen, Inc.	Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
US20060073150A1 (en)	2001-09-06	2006-04-06	Mary Faris	Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
US7335731B2 (en)	2000-07-25	2008-02-26	Genentech, Inc.	PRO4332 polypeptides
EP1666490A3 (en) *	2000-07-25	2006-11-02	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002048370A2 (en)	2000-10-31	2002-06-20	Diadexus, Inc.	Compositions and methods relating to colon specific genes and proteins
US20020111302A1 (en) *	2000-11-30	2002-08-15	Y. Tom Tang	Novel nucleic acids and polypeptides
US7736654B2 (en)	2001-04-10	2010-06-15	Agensys, Inc.	Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20030119112A1 (en)	2001-06-20	2003-06-26	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7494646B2 (en)	2001-09-06	2009-02-24	Agensys, Inc.	Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
EP1439235A4 (en)	2001-10-12	2006-01-18	Astellas Pharma Inc	Method of screening cell death inhibitor
SI1997512T1 (en)	2002-04-09	2014-03-31	Biogen Idec Ma Inc.	Methods for treating TWEAK-related conditions
AU2003900747A0 (en) *	2003-02-18	2003-03-06	Garvan Institute Of Medical Research	Diagnosis and treatment of pancreatic cancer
US20050025763A1 (en)	2003-05-08	2005-02-03	Protein Design Laboratories, Inc.	Therapeutic use of anti-CS1 antibodies
US7709610B2 (en)	2003-05-08	2010-05-04	Facet Biotech Corporation	Therapeutic use of anti-CS1 antibodies
WO2005019258A2 (en) *	2003-08-11	2005-03-03	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
ES2339710T5 (en)	2003-09-23	2017-10-05	University Of North Carolina At Chapel Hill	Cells that coexpress vitamin K reductase and vitamin K dependent protein and use them to improve the productivity of said vitamin K dependent protein
DK2272951T3 (en) *	2003-10-14	2014-10-13	Baxter Int	VKORC1 (vitamin K epoxide feedback polypeptide), a therapeutic target for coumarin and its derivatives
WO2005076003A2 (en) *	2004-02-03	2005-08-18	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with plasma glutamate carboxypeptidase (pgcp)
US20050186577A1 (en)	2004-02-20	2005-08-25	Yixin Wang	Breast cancer prognostics
PT1742966E (en)	2004-04-22	2014-02-05	Agensys Inc	Antibodies and molecules derived therefrom that bind to steap-1 proteins
SI1794174T1 (en)	2004-09-01	2012-09-28	Dynavax Tech Corp	Methods and compositions for inhibition of innate immune responses and autoimmunity
WO2006026808A1 (en) *	2004-09-07	2006-03-16	Telethon Institute For Child Health Research	Method of diagnosing and/or predicting the development of an allergic disorder
WO2006026807A1 (en) *	2004-09-07	2006-03-16	Telethon Institute For Child Health Research	Agents for treatment or prevention of an allergic disorder
DK2529619T3 (en)	2005-02-17	2016-01-11	Biogen Ma Inc	Treatment of neurological disorders
DK1853700T3 (en)	2005-02-28	2013-01-07	Baxter Int	RECOMBINANT CO-EXPRESSION OF VITAMIN-K-EPOXID REDUCTASE UNIT 1 TO IMPROVE VITAMIN-K-DEPENDED PROTEIN EXPRESSION
US20090325226A1 (en)	2005-03-15	2009-12-31	Stafford Darrel W	Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
CA2607697C (en)	2005-05-10	2015-01-06	Biogen Idec Ma Inc.	Treating and evaluating inflammatory disorders
WO2006138219A2 (en)	2005-06-13	2006-12-28	Biogen Idec Ma Inc.	Methods of diagnosis / prognosis of inflammatory conditions
GB2470843B (en) *	2005-09-01	2011-04-13	Florey Howard Inst	Models and methods for the assessment of potential therapeutic agents for the modulation of NDFIP1-NEDD4 interactions
GB0521488D0 (en) *	2005-10-21	2005-11-30	Ares Trading Sa	Integral membrane protein
US7572618B2 (en)	2006-06-30	2009-08-11	Bristol-Myers Squibb Company	Polynucleotides encoding novel PCSK9 variants
MX2009003938A (en)	2006-10-27	2009-04-24	Genentech Inc	Antibodies and immunoconjugates and uses therefor.
JP5588175B2 (en)	2006-11-07	2014-09-10	メルク・シャープ・アンド・ドーム・コーポレーション	PCSK9 antagonist
US8093222B2 (en)	2006-11-27	2012-01-10	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
EP2142217B1 (en) *	2007-03-27	2014-11-05	Merck Sharp & Dohme Corp.	Method for detecting autoprocessed, secreted pcsk9
JOP20080381B1 (en)	2007-08-23	2023-03-28	Amgen Inc	Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
CA2703931C (en)	2007-10-26	2016-08-16	Dynavax Technologies Corporation	Methods and compositions for inhibition of immune responses and autoimmunity
EP3536336A1 (en) *	2007-11-30	2019-09-11	Siemens Healthcare Diagnostics Inc.	Adiponectin receptor fragments and methods of use
AR070315A1 (en)	2008-02-07	2010-03-31	Merck & Co Inc	ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
AR070316A1 (en)	2008-02-07	2010-03-31	Merck & Co Inc	PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
WO2010068526A1 (en)	2008-12-12	2010-06-17	Merck Sharp & Dohme Corp.	Pcsk9 immunoassay
IN2012DN03824A (en)	2009-10-30	2015-08-28	Merck Sharp & Dohme
US8802827B2 (en)	2009-10-30	2014-08-12	Merck Sharp & Dohme Corp.	AX1 PCSK9 antagonists
BR112012032240A2 (en)	2010-06-16	2019-09-24	Dynavax Technologies Corporation	treatment method using tlr7 and / or tlr9 inhibitors
CA2810928A1 (en)	2010-09-22	2012-03-29	Alios Biopharma, Inc.	Substituted nucleotide analogs
EP2655607A4 (en)	2010-12-21	2014-05-14	Univ North Carolina	METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ACTIVE PROTEINS DEPENDENT ON VITAMIN K
CA2860234A1 (en)	2011-12-22	2013-06-27	Alios Biopharma, Inc.	Substituted phosphorothioate nucleotide analogs
HK1206362A1 (en)	2012-03-21	2016-01-08	Alios Biopharma, Inc.	Solid form of thiophosphoramidate nucleotide prodrug
US9012427B2 (en)	2012-03-22	2015-04-21	Alios Biopharma, Inc.	Pharmaceutical combinations comprising a thionucleotide analog
US8883157B1 (en)	2013-12-17	2014-11-11	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
US8986694B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Targeting human nav1.7 variants for treatment of pain
US8980273B1 (en)	2014-07-15	2015-03-17	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9914769B2 (en)	2014-07-15	2018-03-13	Kymab Limited	Precision medicine for cholesterol treatment
US9017678B1 (en)	2014-07-15	2015-04-28	Kymab Limited	Method of treating rheumatoid arthritis using antibody to IL6R
US9045545B1 (en)	2014-07-15	2015-06-02	Kymab Limited	Precision medicine by targeting PD-L1 variants for treatment of cancer
US9023359B1 (en)	2014-07-15	2015-05-05	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en)	2014-07-15	2015-05-19	Kymab Limited	Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9045548B1 (en)	2014-07-15	2015-06-02	Kymab Limited	Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en)	2014-07-15	2015-02-03	Kymab Limited	Method of treating rheumatoid arthritis using antibody to IL6R
US9051378B1 (en)	2014-07-15	2015-06-09	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
US9067998B1 (en)	2014-07-15	2015-06-30	Kymab Limited	Targeting PD-1 variants for treatment of cancer
US8986691B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8992927B1 (en)	2014-07-15	2015-03-31	Kymab Limited	Targeting human NAV1.7 variants for treatment of pain
US9682218B2 (en)	2013-12-23	2017-06-20	Carefusion 2200, Inc.	Pleurodesis device and method
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
US9150660B1 (en)	2014-07-15	2015-10-06	Kymab Limited	Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en)	2014-07-15	2015-09-22	Kymab Limited	Precision medicine by targeting human NAV1.9 variants for treatment of pain
BR112018076260A2 (en)	2016-06-20	2019-03-26	Kymab Limited	antibody or fragment thereof that specifically binds to hpd-11, bispecific antibody or fusion protein, use of an antibody or fragment, method, pharmaceutical composition, modulation method, inhibition method, treatment method, nucleic acid, vector, host and immunocytocin
US11779604B2 (en)	2016-11-03	2023-10-10	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses and methods
GB2572918B (en)	2016-12-23	2023-02-15	Harvard College	Gene editing of PCSK9
BR112019018767A2 (en)	2017-04-03	2020-05-05	Hoffmann La Roche	antibodies, bispecific antigen binding molecule, one or more isolated polynucleotides, one or more vectors, host cell, method for producing an antibody, pharmaceutical composition, uses, method for treating a disease in an individual and invention
EP3642383B1 (en)	2017-06-22	2022-12-21	The Procter & Gamble Company	Films including a water-soluble layer and a vapor-deposited inorganic coating
US11192139B2 (en)	2017-06-22	2021-12-07	The Procter & Gamble Company	Films including a water-soluble layer and a vapor-deposited organic coating
BR112022020407A2 (en)	2020-04-09	2023-05-02	Verve Therapeutics Inc	BASE EDITION OF PCSK9 AND METHODS OF USING IT FOR TREATMENT OF DISEASES

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000004140A1 (en) *	1998-07-15	2000-01-27	Human Genome Sciences, Inc.	71 human secreted proteins
WO2002026931A2 (en) *	2000-09-25	2002-04-04	Human Genome Sciences, Inc.	71 human secreted proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100236393B1 (en) *	1996-02-02	1999-12-15	나까니시 히로유끼	A pharmaceutical preparation containing a human growth hormone
US5858716A (en) *	1997-05-30	1999-01-12	Smithkline Beecham Corporation	H2CAA71 polynucleotides

2002
- 2002-03-19 EP EP02782476A patent/EP1414845A4/en not_active Withdrawn
- 2002-03-19 CA CA002441702A patent/CA2441702A1/en not_active Abandoned
- 2002-03-19 CA CA002441840A patent/CA2441840A1/en not_active Abandoned
- 2002-03-19 AU AU2002324424A patent/AU2002324424A1/en not_active Abandoned
- 2002-03-19 WO PCT/US2002/008123 patent/WO2002102993A2/en not_active Ceased
- 2002-03-19 CA CA002441416A patent/CA2441416A1/en not_active Abandoned
- 2002-03-19 WO PCT/US2002/008279 patent/WO2002090526A2/en not_active Ceased
- 2002-03-19 AU AU2002326293A patent/AU2002326293A1/en not_active Abandoned
- 2002-03-19 AU AU2002354719A patent/AU2002354719A1/en not_active Abandoned
- 2002-03-19 EP EP02723499A patent/EP1379264A4/en not_active Withdrawn
- 2002-03-19 CA CA002441755A patent/CA2441755A1/en not_active Abandoned
- 2002-03-19 WO PCT/US2002/008277 patent/WO2003038063A2/en not_active Ceased
- 2002-03-19 AU AU2002363296A patent/AU2002363296A1/en not_active Abandoned
- 2002-03-19 EP EP02759068A patent/EP1404702A4/en not_active Withdrawn
- 2002-03-19 WO PCT/US2002/008124 patent/WO2003004622A2/en not_active Ceased
- 2002-03-19 CA CA002441397A patent/CA2441397A1/en not_active Abandoned
- 2002-03-19 AU AU2002332391A patent/AU2002332391A1/en not_active Abandoned
- 2002-03-19 EP EP02749512A patent/EP1381622A2/en not_active Withdrawn
- 2002-03-19 EP EP02780789A patent/EP1423134A2/en not_active Withdrawn
- 2002-03-19 WO PCT/US2002/009785 patent/WO2002095010A2/en not_active Ceased
- 2002-03-19 WO PCT/US2002/008276 patent/WO2002076488A1/en not_active Ceased
- 2002-03-19 CA CA002441417A patent/CA2441417A1/en not_active Abandoned
- 2002-03-19 AU AU2002320013A patent/AU2002320013A1/en not_active Abandoned
- 2002-03-19 CA CA002441832A patent/CA2441832A1/en not_active Abandoned
- 2002-03-19 WO PCT/US2002/008278 patent/WO2002102994A2/en not_active Ceased
- 2002-03-19 EP EP02799146A patent/EP1390390A4/en not_active Withdrawn
- 2002-03-19 EP EP02760994A patent/EP1379132A4/en not_active Withdrawn

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000004140A1 (en) *	1998-07-15	2000-01-27	Human Genome Sciences, Inc.	71 human secreted proteins
WO2002026931A2 (en) *	2000-09-25	2002-04-04	Human Genome Sciences, Inc.	71 human secreted proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HSU SHEAU YU ET AL: "Characterization of two LGR genes homologous to gonadotropin and thyrotropin receptors with extracellular leucine-rich repeats and a G protein-coupled, seven-transmembrane region", MOLECULAR ENDOCRINOLOGY, vol. 12, no. 12, December 1998 (1998-12-01), pages 1830 - 1845, XP002528150, ISSN: 0888-8809 *
LOH E D ET AL: "Molecular Characterization of a Novel Glycoprotein Hormone G-Protein-Coupled Receptor", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 282, no. 3, 6 April 2001 (2001-04-06), pages 757 - 764, XP003002810, ISSN: 0006-291X *

Also Published As

Publication number	Publication date
AU2002320013A1 (en)	2002-11-18
WO2002090526A3 (en)	2003-10-30
EP1404702A4 (en)	2009-07-08
CA2441416A1 (en)	2003-01-16
EP1404702A2 (en)	2004-04-07
WO2002095010A3 (en)	2004-02-12
AU2002354719A1 (en)	2003-01-21
WO2003038063A2 (en)	2003-05-08
EP1423134A2 (en)	2004-06-02
WO2002102994A2 (en)	2002-12-27
WO2003004622A2 (en)	2003-01-16
AU2002324424A1 (en)	2002-12-03
CA2441417A1 (en)	2002-11-14
WO2002102993A2 (en)	2002-12-27
EP1414845A2 (en)	2004-05-06
AU2002332391A1 (en)	2003-01-02
EP1390390A2 (en)	2004-02-25
CA2441397A1 (en)	2002-10-03
EP1381622A2 (en)	2004-01-21
WO2002095010A2 (en)	2002-11-28
WO2002102993A3 (en)	2004-03-25
AU2002326293A1 (en)	2003-01-02
WO2003004622A3 (en)	2004-02-19
WO2002076488A1 (en)	2002-10-03
CA2441840A1 (en)	2002-11-28
AU2002363296A1 (en)	2003-05-12
EP1379132A2 (en)	2004-01-14
EP1379264A1 (en)	2004-01-14
WO2002102994A3 (en)	2003-07-24
CA2441755A1 (en)	2003-05-08
EP1379132A4 (en)	2009-07-01
CA2441832A1 (en)	2002-12-27
WO2003038063A3 (en)	2003-12-11
EP1414845A4 (en)	2009-07-08
WO2002090526A2 (en)	2002-11-14
CA2441702A1 (en)	2002-12-27
EP1379264A4 (en)	2009-07-08

Publication	Publication Date	Title
EP1379132A4 (en)	2009-07-01	Human secreted proteins
EP1506398A4 (en)	2005-06-29	Human secreted proteins
GB0218205D0 (en)	2002-09-11	Human ZZAP1 protein
EP1251863A4 (en)	2005-03-02	22 human secreted proteins
AU2002361452A8 (en)	2003-07-09	Secreted proteins
IL162598A0 (en)	2005-11-20	Secreted protein
AU2002232596A1 (en)	2002-06-24	Secreted human proteins
EP1368468A4 (en)	2005-02-16	83 human secreted proteins
AU2002354803A8 (en)	2008-03-13	Secreted proteins
AU2003301843A8 (en)	2004-06-07	157 human secreted proteins
EP1385977A4 (en)	2005-02-16	Secreted proteins
AU2001294719A1 (en)	2002-04-08	Secreted human proteins
EP1370651A4 (en)	2005-04-06	70 human secreted proteins
EP1417224A4 (en)	2005-08-10	Secreted proteins
AU2002365153A1 (en)	2003-06-30	41 human secreted proteins
EP1404807A4 (en)	2005-03-23	20 human secreted proteins
AU2002246998A1 (en)	2002-07-30	50 human secreted proteins
AU2002348034A8 (en)	2009-07-30	16 human secreted proteins
AU2002254275A1 (en)	2002-10-08	Human secreted proteins
AU2002303843A8 (en)	2007-09-20	Secreted proteins
AU2003211136A8 (en)	2003-10-08	6 human secreted proteins
AU2002247189A1 (en)	2002-09-12	70 human secreted proteins
AU2002253985A1 (en)	2002-09-12	83 human secreted proteins
AU2002332483A1 (en)	2003-02-24	13 human secreted proteins
EP1443818A4 (en)	2006-03-08	Novel secreted proteins and their uses

Legal Events

Date	Code	Title	Description
2004-01-09	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2004-02-25	17P	Request for examination filed	Effective date: 20031021
2004-02-25	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
2004-02-25	AX	Request for extension of the european patent	Extension state: AL LT LV MK RO SI
2009-07-08	A4	Supplementary search report drawn up and despatched	Effective date: 20090605
2010-01-29	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2010-03-03	18D	Application deemed to be withdrawn	Effective date: 20090904